IL2 and graft versus host disease: While low-dose IL-2 has been used to expand the endogenous pool of Tregs and successfully control chronic graft-versus-host disease (GVHD) and selected autoimmune diseases (27–29), similar efficacy has not been observed in organ transplantation (30, 31).